Skip to main content

UNC13A Gene Brings New Hope for ALS Disease-Modifying Drugs

Neuroscience Bulletin volume 38, pages 1431–1434 (2022)Cite this article

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

USD 39.95

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Fig. 1

References

  1. Wen X, An P, Li H, Zhou Z, Sun Y, Wang J. Tau accumulation via reduced autophagy mediates GGGGCC repeat expansion-induced neurodegeneration in Drosophila model of ALS. Neurosci Bull 2020, 36: 1414–1428.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Petrov D, Mansfield C, Moussy A, Hermine O. ALS clinical trials review: 20 years of failure. Are we any closer to registering a new treatment? Front Aging Neurosci 2017, 9: 68.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Ling JP, Pletnikova O, Troncoso JC, Wong PC. TDP-43 repression of nonconserved cryptic exons is compromised in ALS-FTD. Science 2015, 349: 650–655.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Ma XR, Prudencio M, Koike Y, Vatsavayai SC, Kim G, Harbinski F, et al. TDP-43 represses cryptic exon inclusion in the FTD–ALS gene UNC13A. Nature 2022, 603: 124–130.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Brown AL, Wilkins OG, Keuss MJ, Hill SE, Zanovello M, Lee WC, et al. TDP-43 loss and ALS-risk SNPs drive mis-splicing and depletion of UNC13A. Nature 2022, 603: 131–137.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. van Es MA, Veldink JH, Saris CGJ, Blauw HM, van Vught PWJ, Birve A, et al. Genome-wide association study identifies 19p13.3 (UNC13A) and 9p21.2 as susceptibility loci for sporadic amyotrophic lateral sclerosis. Nat Genet 2009, 41: 1083–1087.

    Article  PubMed  Google Scholar 

  7. Chiò A, Mora G, Restagno G, Brunetti M, Ossola I, Barberis M, et al. UNC13A influences survival in Italian amyotrophic lateral sclerosis patients: A population-based study. Neurobiol Aging 2013, 34: 357.e1-357.e5.

    Article  Google Scholar 

  8. Quade B, Camacho M, Zhao X, Orlando M, Trimbuch T, Xu J, et al. Membrane bridging by Munc13-1 is crucial for neurotransmitter release. eLife 2019, 8: e42806.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Böhme MA, Beis C, Reddy-Alla S, Reynolds E, Mampell MM, Grasskamp AT, et al. Active zone scaffolds differentially accumulate Unc13 isoforms to tune Ca2+ channel–vesicle coupling. Nat Neurosci 2016, 19: 1311–1320.

    Article  PubMed  Google Scholar 

  10. Varoqueaux F, Sons MS, Plomp JJ, Brose N. Aberrant morphology and residual transmitter release at the Munc13-deficient mouse neuromuscular synapse. Mol Cell Biol 2005, 25: 5973–5984.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Vérièpe J, Fossouo L, Parker JA. Neurodegeneration in C. elegans models of ALS requires TIR-1/Sarm1 immune pathway activation in neurons. Nat Commun 2015, 6: 7319.

    Article  PubMed  Google Scholar 

  12. Matsuo M. Antisense oligonucleotide-mediated exon-skipping therapies: Precision medicine spreading from Duchenne muscular dystrophy. JMA J 2021, 4: 232–240.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Roberts TC, Langer R, Wood MJA. Advances in oligonucleotide drug delivery. Nat Rev Drug Discov 2020, 19: 673–694.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Choi E, Koo T. CRISPR technologies for the treatment of Duchenne muscular dystrophy. Mol Ther 2021, 29: 3179–3191.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. McDonald CM, Campbell C, Torricelli RE, Finkel RS, Flanigan KM, Goemans N, et al. Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017, 390: 1489–1498.

    Article  CAS  PubMed  Google Scholar 

  16. Kim G, Gautier O, Tassoni-Tsuchida E, Ma XR, Gitler AD. ALS genetics: Gains, losses, and implications for future therapies. Neuron 2020, 108: 822–842.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Wu LS, Cheng WC, Chen CY, Wu MC, Wang YC, Tseng YH, et al. Transcriptomopathies of pre- and post-symptomatic frontotemporal dementia-like mice with TDP-43 depletion in forebrain neurons. Acta Neuropathol Commun 2019, 7: 50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Yang C, Qiao T, Yu J, Wang H, Guo Y, Salameh J, et al. Low-level overexpression of wild type TDP-43 causes late-onset, progressive neurodegeneration and paralysis in mice. PLoS One 2022, 17: e0255710.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Klim JR, Williams LA, Limone F, Guerra San Juan I, Davis-Dusenbery BN, Mordes DA, et al. ALS-implicated protein TDP-43 sustains levels of STMN2, a mediator of motor neuron growth and repair. Nat Neurosci 2019, 22: 167–179.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Melamed Z, López-Erauskin J, Baughn MW, Ouyang Z, Drenner K, Sun Y, et al. Premature polyadenylation-mediated loss of stathmin-2 is a hallmark of TDP-43-dependent neurodegeneration. Nat Neurosci 2019, 22: 180–190.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Fiesel FC, Weber SS, Supper J, Zell A, Kahle PJ. TDP-43 regulates global translational yield by splicing of exon junction complex component SKAR. Nucleic Acids Res 2012, 40: 2668–2682.

    Article  CAS  PubMed  Google Scholar 

  22. Shiga A, Ishihara T, Miyashita A, Kuwabara M, Kato T, Watanabe N, et al. Alteration of POLDIP3 splicing associated with loss of function of TDP-43 in tissues affected with ALS. PLoS One 2012, 7: e43120.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, National Center for Neurological Disorders, Huashan Hospital, Fudan University, Shanghai, 200040, China

    Xi Chen & Yi Dong

  2. Department of Gerontology, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, 200233, China

    Heling Chu

Authors
  1. Xi Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Heling Chu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yi Dong
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Heling Chu or Yi Dong.

Ethics declarations

Conflict of interest

There is no conflict of interest.

Rights and permissions

Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Chen, X., Chu, H. & Dong, Y. UNC13A Gene Brings New Hope for ALS Disease-Modifying Drugs. Neurosci. Bull. 38, 1431–1434 (2022). https://doi.org/10.1007/s12264-022-00924-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12264-022-00924-8